The G53D Mutation in Kir6.2 (KCNJ11) Is Associated with Neonatal Diabetes and Motor Dysfunction in Adulthood that Is Improved with Sulfonylurea Therapy

Joseph C. Koster, Francesco Cadario, Cinzia Peruzzi, Carlo Colombo, Colin G. Nichols, and Fabrizio Barbetti

Department of Cell Biology and Physiology (J.C.K., C.G.N.), Washington University School of Medicine, St. Louis, Missouri 63110; Department of Pediatrics (F.C.), Interdisciplinary Research Center for Autoimmune Disease, A. Avogadro University of Eastern Piedmont, and Division of Child Neurology and Psychiatry (C.P.), Azienda Ospedaliera “Maggiore della Carità,” 28100 Novara, Italy; Bambino Gesù Children’s Hospital (C.C., F.B.), Instituto di Ricovero e Cura a Carattere Scientifico, 00164 Rome, Italy; S. Raffaele Scientific Park Foundation (F.B.), 00128 Rome, Italy; and Department of Internal Medicine (F.B.), University of Tor Vergata, 00133 Rome, Italy

Context: Mutations in the Kir6.2 subunit (KCNJ11) of the ATP-sensitive potassium channel (KATP) underlie neonatal diabetes mellitus. In severe cases, Kir6.2 mutations underlie developmental delay, epilepsy, and neonatal diabetes (DEND). All Kir6.2 mutations examined decrease the ATP inhibition of KATP, which is predicted to suppress electrical activity in neurons (peripheral and central), muscle, and pancreas. Inhibitory sulfonylureas (SUs) have been used successfully to treat diabetes in patients with activating Kir6.2 mutations. There are two reports of improved neurological features in SU-treated DEND patients but no report of such improvement in adulthood.

Objective: The objective of the study was to determine the molecular basis of intermediate DEND in a 27-yr-old patient with a KCNJ11 mutation (G53D) and the patient’s response to SU therapy.

Design: The G53D patient was transferred from insulin to gliclazide and then to glibenclamide over a 160-d period. Motor function was assessed throughout. Electrophysiology assessed the effect of the G53D mutation on KATP activity.

Results: The G53D patient demonstrated improved glycemic control and motor coordination with SU treatment, although glibenclamide was more effective than gliclazide. Reconstituted G53D channels exhibit reduced ATP sensitivity, which is predicted to suppress electrical activity in vivo. G53D channels coexpressed with SUR1 (the pancreatic and neuronal isoform) exhibit high-affinity block by gliclazide but are insensitive to block when coexpressed with SUR2A (the skeletal muscle isoform). High-affinity block by glibenclamide is present in G53D channels coexpressed with either SUR1 or SUR2A.

Conclusion: The results demonstrate that SUs can resolve motor dysfunction in an adult with intermediate DEND and that this improvement is due to inhibition of the neuronal but not skeletal muscle KATP. (J Clin Endocrinol Metab 93: 1054–1061, 2008)
closure of $K_{\text{ATP}}$ channels, membrane depolarization, voltage-driven influx of $Ca^{2+}$, and $Ca^{2+}$-dependent insulin release. Disruption of $K_{\text{ATP}}$ activity is predicted to impair insulin release and result in inappropriate serum insulin levels at all blood glucose concentration.

It is now well established that $K_{\text{ATP}}$ overactivity contributes to neonatal diabetes mellitus, a disease characterized by an insulin-requiring hyperglycemia diagnosed before 6 months of age (1, 2). Specifically, heterozygous activating mutations in $K_{\text{ATP}}$ (both the Kir6.2 and SUR1 subunits) are causal in permanent (PNDM) and transient (TNDM) forms of neonatal diabetes mellitus in humans (1, 3–10). In approximately one third of the cases, $K_{\text{ATP}}$ mutations are associated with developmental delay (both motor and intellectual), epilepsy, and neonatal diabetes (DEND syndrome), and extrapancreatic symptoms are likely the result of overactive $K_{\text{ATP}}$ in muscle, peripheral nerves, and/or brain (11). In intermediate DEND the patient exhibits developmental delay and neonatal diabetes but not epilepsy, and in most cases, this form of DEND is associated with the V59M mutation. Significantly, sulfonylurea (SU) compounds that specifically inhibit $K_{\text{ATP}}$ and thereby stimulate insulin secretion have proven a valuable alternative to insulin therapy in treating the hyperglycemia in patients with activating $K_{\text{ATP}}$ mutations (12). To date, 91% of patients (68 of 75) have successfully switched from insulin to oral sulfonylureas with improvement or maintenance of glycemic control, although the success rate is lower in patients with DEND symptoms (77%; 10 of 14) (5, 12–15). Notably, an infant and a 3-yr-old patient with DEND syndrome have exhibited improved motor features with SU treatment, in addition to resolution of the diabetes (13, 14).

The mature $K_{\text{ATP}}$ channel exists as a hetero-octomer of four pore-forming Kir6.2 subunits ($KCNJ11$) and four regulatory sulfonylurea receptors (SUR$_1$; e.g., ABCC8) (17–19). The Kir6.2 subunit contains the binding site for inhibitory ATP (20, 21), whereas the SUR subunit confers channel stimulation by $Mg$ nucleotides (22) and inhibition to SU drugs (23). With respect to SU block, an added level complexity arises from the existence of multiple SUR isoforms (SUR1, SUR2A, and SUR2B), which exhibit differential tissue expression and SU sensitivities (24). The skeletal muscle $K_{\text{ATP}}$ (Kir6.2 + SUR2A) channel, for example, is less sensitive to both glibenclamide and gliclazide block than the pancreatic/neuronal $K_{\text{ATP}}$ (Kir6.2 + SUR1) (24, 25). High-affinity gliclazide block is absent in Kir6.2 + SUR2A channels, whereas high-affinity glibenclamide block is reduced approximately 3-fold relative to Kir6.2 + SUR1 channels.

In the present study, we describe a patient with intermediate DEND who at 27 yr of age was found to carry a heterozygous mutation in Kir6.2 (G53D). The patient was weaned from insulin onto gliclazide and then glibenclamide, resulting in good glycemic control, although glibenclamide treatment required supplemental insulin. Importantly, motor features were improved on both SUs as assessed by increased muscle coordination and an enhanced gait. Mechanistically, the G53D mutation causes severe loss of ATP sensitivity of the $K_{\text{ATP}}$ channel, which is predicted to suppress insulin secretion by the pancreatic $\beta$-cell by preventing electrical activity, and calcium influx. Importantly, the G53D mutation does not appreciably alter SU sensitivity of reconstituted channels, compared with wild-type $K_{\text{ATP}}$. When coexpressed with the skeletal muscle SUR2A isoform, channels are predictably insensitive to gliclazide but exhibit high-affinity glibenclamide block when coexpressed with the pancreatic and neuronal SUR1 isoform. Conversely, glibenclamide inhibits both skeletal muscle $K_{\text{ATP}}$ and neuronal/pancreatic $K_{\text{ATP}}$ similarly. Taken together, these data indicate that an adult (intermediate) DEND patient with an activating Kir6.2 mutation can still benefit from SU therapy both in terms of glycemic control and improved motor function. Moreover, the combined functional and clinical data suggest that improved motor function is due to inhibition of $K_{\text{ATP}}$ in central nerves and not the skeletal muscle $K_{\text{ATP}}$.

Patient and Methods

Genetics and molecular biology

Total genomic DNA was isolated from nonnucleated, whole blood using the DNeasy tissue isolation kit (QIAGEN, Valencia, CA). The intronless $KCNJ11$ gene was amplified in three overlapping fragments by the PCR and directly sequenced as described previously (4). The identified G53D mutation was engineered into Kir6.2 cDNA of pCMV6B using the Quikchange site-directed mutagenesis kit (Stratagene, La Jolla, CA), and confirmed by direct sequencing.

Clinical studies: recording of neurological examination before and after transfer from insulin to SUs

Upon detection of a $KCNJ11$ mutation (G53D), an attempt was made to transfer the patient from insulin therapy to oral treatment with SU with close monitoring of metabolic control. With the aim of documenting any change in motor performance induced by SUs, three movies of a standard neurological examination were recorded: 1) during insulin therapy (basal), 2) at the end of 20 d of therapy with high doses of gliclazide (720 mg/d) (first oral treatment), and 3) at the end of 25 d with high doses of glibenclamide (45 mg/d) (second oral treatment) (Fig. 1A). There was no washout between SU treatments. Informed consent was obtained from the patient.

Expression of wild-type and mutant $K_{\text{ATP}}$ channels in COSm6 cells

COSm6 cells were plated at a density of approximately $2.5 \times 10^5$ cells/well (30 mm 6 well dishes) and cultured in DMEM plus 10 mM glucose, supplemented with fetal calf serum (10%). COSm6 cells were transfected with cDNA using FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN). Total DNA (0.3 $\mu$g of Kir6.2(WT) or Kir6.2(G53D) plus 0.5 $\mu$g of SUR1(WT) or SUR2A(WT) plus 0.3 $\mu$g green fluorescent protein as a marker for transfection) was mixed with FuGENE6 and precipitated for 1h. Cells were incubated in the presence of the transfection mixture for 12–24 h and then plated on sterile glass coverslips overnight before patch-clamp experiments.

Electrophysiological methods

Patch-clamp experiments were performed at room temperature in an oil-gate chamber that allowed the solution bathing the exposed surface of the isolated patch to be changed rapidly. COSm6 cells that fluoresced green under UV illumination were selected for patch clamping 3–5 d after transfection. Membrane patches were voltage clamped using a CV-4 headstage, an Axopatch 1-D amplifier, a Digidata 1322A digitizer board (all from Axon Instruments, Union City, CA), and a MP-225 micromanipulator (Sutter Instrument Co., Novato, CA). All currents were measured at a membrane potential of $-50$ mV (pipette voltage $= +50$ mV). Data were collected using the pClamp 8.2 software suite (Axon Instru-
Koster et al. Intermediate DEND Caused by G53D Mutation in KCNJ11

Results are presented as mean ± SEM. Statistical tests and P values are noted in figure legends where appropriate.

Quantitative analysis of ATP and SU inhibition

The ATP dose response was quantified by fitting the raw data with a Hill equation:

\[ I_{rel} = \frac{100}{1 + (ATP/k_{1/2})^H} \]  

(Eq. 2)

where \( I_{rel} \) is the current relative to that in the absence of ATP, ATP is the ATP concentration, \( k_{1/2} \) is the half-maximal inhibitory ATP concentration, and \( H \) is the Hill coefficient, which was fixed at 1.3. Dose-response curves for gliclazide inhibition were described by the sum of two Hill equations (reflecting two components of inhibition) (26):

\[ I_{rel} = f\left[1 + (SU/k_1)^{1H}\right] + \left[1 - f\right]\left[1 + (SU/k_2)^{1H}\right] \]  

(Eq. 3)

where \( f \) is the fraction of high-affinity block, SU is the SU concentration, \( k_1 \) and \( k_2 \) are the half-maximal concentrations of high- and low-affinity block, respectively, and \( H \) is the Hill coefficient for either the high-affinity (HA) or low-affinity block (HB).

Results

Genotyping and clinical description of G53D patient

In the present study, the female patient was born at 41 wk after an uneventful pregnancy (but intrauterine developmental delay as recorded by ultrasound), with a birth weight of 2550 g (less than the third centile). Thirty-six days after birth, the patient was transferred to the local neonatal intensive care unit because of failure to thrive. She presented with dehydration, hyperglycemia (28.7 mmol/l), but no ketoacidosis (pH 7.34). Therapy was started with regular insulin at the dose of 0.9 U/kg.d and then reduced to 0.65 U/kg.d. Type 1 diabetes autoantibodies were not assessed at the time of diabetes diagnosis, although both islet cell antibodies and glutamic acid decarboxylase autoantibodies tests were negative 10 yr after the onset of the disease. At physical examination a mild dysmorphic feature (ocular hypertelorism) was present. A mild developmental delay was noted because she was unable to sit unaided at the age of 6–7 months. The patient began speaking at the age of 20 months and attended public school between the ages of 6 and 13 yr with a backup teacher. Patient growth was normal, with menarche at 12 yr of age. As an adult of 27 yr of age (supplemental video S1, Patient growth was normal, with menarche at 12 yr of age. As an adult of 27 yr of age (supplemental video S1), she exhibited a slow gait and performed poorly on numerous coordination tests (walking on heels or toes, walking on a single line, hopping on one leg, and touching finger to nose). All physical observations were indicative of a mild ataxia. Sequencing of the patient’s KCNJ11 (Kir6.2) gene revealed a heterozygous mutation, G53D. DNA samples were not available from either parent; however, neither parent was diabetic, which would indicate that the G53D mutation arose de novo. The G53D mutation has previously been reported in a patient with intermediate DEND, which included seizures during infancy and an abnormal electroencephalogram (9).
Improved motor features after transfer from insulin to SU therapy

After the genotyping the G53D patient was progressively transferred from insulin (0.65 UI/kg•d) to the SU gliclazide and then to glibenclamide (Fig. 1A). Gliclazide therapy had only a slight effect on glycemic control, although the insulin requirement was progressively reduced from 40 U/d to 11 U/d during the treatment period. Thus, despite a maximum dose of gliclazide (720 mg/d), insulin therapy could not be discontinued. In contrast, excellent glycemic control with complete weaning from insulin was attained with glibenclamide therapy (30 mg/d). During this period, hemoglobin A1c values progressively decreased from 8.4% (d 36) to the current level of 5.5% (d 370). C-peptide levels were undetectable during gliclazide therapy (lower limit of detection ≥ 0.1 ng/ml), and patient lost body weight (from 61.6 to 56.2 kg; Fig. 1B). Serum C-peptide became detectable on glibenclamide therapy with no further loss of body weight. Importantly, improved motor function, as confirmed by a neurologist, was observed when the G53D patient was switched from insulin (40 U/d) to gliclazide (after 20 d on 720 mg/d) [supplemental Fig. S1, published as supplemental data on The Endocrine Society’s Journals Online Web site at http://jcem.endojournals.org; compare left video panel (before) to right video panel (after) gliclazide treatment]. A minor further improvement over gliclazide was observed after switching to glibenclamide (after 2.5 d on 25 mg/d) [supplemental Fig. S2, published as supplemental data on The Endocrine Society’s Journals Online Web site at http://jcem.endojournals.org; compare left panel (gliclazide) with right panel (glibenclamide)].

Increased on-cell activity of G53D channels correlates with a reduced ATP sensitivity

Homology modeling with known K⁺-channel structures places the G53 residue in the cytoplasmic N terminus of Kir6.2 but outside the ATP-binding pocket itself (27). Residue G53 resides in the slide-helix region of the channel that is implicated in channel gating. To examine the molecular consequences of the G53D mutation, a mutant Kir6.2 subunit containing the G53D mutation was coexpressed with the wild-type SUR1 subunit, and channel activity in intact cells was screened by ⁸⁶Rb⁺-efflux. As shown in Fig. 2, A and B, efflux from cells transfected with wild-type KATP channels, and untransfected controls (Unt). All transfections were done in parallel. Graphs show compiled data (mean ± SEM) from four to six experiments. C, Rate constants for KATP-dependent efflux (k₂) in basal conditions relative to metabolic inhibition (MI) for WT, heteromeric, or homomeric KATP channels. Data were fit with a double-exponential equation to obtain rate constants for KATP-dependent efflux, k₂ (see Patient and Methods). *, P < 0.05 and **, P < 0.001, compared with wild-type KATP by unpaired Student’s t test.

FIG. 2. Increased basal activity in intact cells expressing KATP (G53D) channels. Relative efflux of ⁸⁶Rb⁺ as a function of time in basal conditions (A) or in the presence of metabolic inhibition (B) for reconstituted wild-type (WT) and mutant KATP channels, and untransfected controls (Unt). All transfections were done in parallel. Graphs show compiled data (mean ± SEM) from four to six experiments.

A, Basal

- Unt
- WT
- 1:1
- G53D

B, Metabolic Inhibition

- Unt
- WT
- 1:1
- G53D

C, Rate constants for KATP-dependent efflux (k₂) in basal conditions relative to metabolic inhibition (MI) for WT, heteromeric, or homomeric KATP channels. Data were fit with a double-exponential equation to obtain rate constants for KATP-dependent efflux, k₂ (see Patient and Methods). *, P < 0.05 and **, P < 0.001, compared with wild-type KATP by unpaired Student’s t test.

During metabolic inhibition (MI) for both homomeric and heteromeric G53D channels, compared with wild-type channels (Fig. 2C). In the pancreatic β-cell, the increased basal flux is expected to suppress electrical activity and reduce insulin secretion and can account for the diabetes in the G53D patient.

To examine the correlation between increased KATP activity in intact cells and ATP sensitivity, the latter was measured directly in excised membrane patches (Fig. 3, A–C). Both heteromeric (G53D + WT) and homomeric (G53D) channels coexpressed with SUR1 exhibited a significant decrease in ATP
The G53D mutation does not alter SU sensitivity

Good glycemic control and improved motor function was observed when the G53D patient was switched from insulin to gliclazide or glibenclamide. However, Kir6.2 mutations can significantly alter SU sensitivity (10, 28). To examine the effect of the G53D mutation on SU sensitivity and to determine whether the improved motor function is likely to be neuronal (Kir6.2 + SUR1) or skeletal muscle (Kir6.2 + SUR2A) in origin, membrane patches from transfected cells were exposed to varying concentration of gliclazide. Consistent with previous reports, Kir6.2 + SUR2A channels do not exhibit high-affinity gliclazide block, whereas Kir6.2 + SUR1 channels exhibit both high and low affinities of inhibition (Fig. 4, A, C, and E) (23). Importantly, the gliclazide sensitivities are not altered in G53D-containing channels (Fig. 4, B, D, and F). Similarly, the G53D mutation does not alter glibenclamide sensitivities, compared with wild-type channels (Fig. 4, G and H). In this case both SUR1- and SUR2A-containing channels are inhibited similarly by the drug. Taken together, these results suggest that improved motor function in the G53D patient is the result of inhibition of the SUR1-based neuronal $K_{ATP}$ rather than the SUR2A-based skeletal muscle $K_{ATP}$.

Discussion

Improvement of neurological features in the G53D patient with SU therapy

In the present study, we identified a Kir6.2 mutation (G53D) in an adult patient with intermediate DEND that is responsive to SU treatment (gliclazide and glibenclamide), although with different efficacies of the two drugs in terms of metabolic control (glibenclamide more effective than gliclazide). When switched to SUs, the patient exhibited a significant improvement in muscle tone, coordination, and gait, as assessed by a neurologist and documented in the supplemental videos (videos S1 and S2). This improvement is most likely a consequence of SU therapy as it coincided with the transfer to SUs and has been maintained up to 12 months. Over this same period, a significant improvement in hemoglobin A1c levels was observed (8% on d 36, 7.1% on d 133, and 5.5% on d 370). Whereas we cannot preclude a contribution from the reduced hypoglycemic episodes, the most likely explanation for the improved neurological features is that the SUs are acting on KATP in neurons and/or muscle. In the skeletal muscle, $K_{ATP}$ is composed of Kir6.2 and almost exclusively the SUR2A isoform (23, 30, 31). In contrast, neuronal $K_{ATP}$ (central and peripheral) is comprised primarily of the Kir6.2 and SUR1 isoforms (32, 33). As shown above, skeletal muscle $K_{ATP}$ channels are insensitive to gliclazide block at therapeutic concentrations (peak concentration = 0.2–0.6 μM, free gliclazide in serum) (34), whereas neuronal channels are highly gliclazide sensitive. These results suggest that the improved motor features result from inhibition of neuronal and not skeletal muscle $K_{ATP}$.

The successful transfer to sulfonylureas in our G53D patient is consistent with previous clinical reports of patients with the common V59M mutation. To date all patients (12 of 12) tested with
Patient and Methods

in 1 deoxyglucose). Intact cells were exposed to differing glibenclamides, and baseline current was calculated for wild-type (WT) and mutant G53D channels. Data points represent the mean ± SEM (n = 3–7 patches). The fitted lines correspond to least-square fits of a double-Hill equation (see Patient and Methods). For WT + SUR1 channels: the half-inhibitory concentration of the high-affinity site (Ki1/2, high) was 0.8 mM, and Hill coefficient of low-affinity site (HB) was 1.2; G53D + SUR1: Ki1/2, high = 5 μM, and HB = 2, and f = 0.6. For WT + SUR2A channels: Ki1/2, low = 0.8 mM, and H = 0.6. For G53D + SUR2A channels: Ki1/2, low = 1.2 mM, and H = 0.6. G and H, Steady-state dependence of 22Rb efflux on glibenclamide for WT and G53D SUR1: Ki1/2 = 92.3 nM, and HB = 2.2.

intermediate DEND due to V59M mutation have been successfully switched to SUs with good glycemic control (5, 12, 15). In one infant (28 months) with the V59M mutation, improved motor features was also noted, in addition to resolution of the diabetes (13). Conversely, a 9-yr-old patient with a V59M mutation did not show amelioration of motor dysfunction (15). Thus, improvement of motor features does necessarily accompany the improved glycemic control in intermediate DEND patients who undergo SU therapy.

Theoretically inhibition of overactive KATP in the presynaptic neurons could restore neurotransmitter release and underlie the improved motor function observed in the G53D patient. The SUs could be targeting KATP in peripheral neurons and/or across the blood brain-barrier and act on KATP in the central neurons of the brain. However, the observations that the patient does not exhibit muscle weakness and that the mild ataxia is improved with SU therapy are consistent with SU action in the brain. In rodent studies, SUs have been shown to accumulate in the brain but at subtherapeutic concentrations (36). Consistent with our conclusion that overactive KATP in the neurons underlies the motor features of the DEND patient, a recent report has described a DEND phenotype in a patient with an activating mutation in the SUR1 isoform, which is expressed in neurons, but not muscle (37).

A potential role for skeletal muscle KATP in peripheral insulin sensitivity

As has been observed previously for PNDM patients with Kir6.2 mutations, significantly higher doses of SUs were required to treat the diabetes of the G53D patient than are typically used to treat type 2 diabetes in adults (12). This anomaly may reflect, in part, the fact that SU block is less efficient when nucleotide inhibition on Kir6.2 is decreased (26, 38). In the case of gliclazide, the patient could not be weaned completely from insulin despite a high therapeutic dose of the drug (720 mg/d, or three times the maximal dose used in type 2 diabetes). Conversely, insulin was successfully discontinued on subsequent transfer to glibenclamide (45 mg/d progressively reduced to 35 mg/d, approximately twice the maximal dose used to treat type 2 diabetes). Because a washout period between the two drugs was not performed, a residual effect of gliclazide (half-life ~10 h) on glibenclamide therapy cannot be excluded. However, we believe that this is unlikely as insulin was discontinued after 6 d of glibenclamide treatment, a point at which gliclazide is completely cleared from the plasma. Because the G53D mutation does not alter SU sensitivities in intact cells (Fig. 4, G and H), the dosing discrepancy may reflect differences in the pharmacokinetics of the two drugs with respect to bioavailability and/or relative efficacy. Indeed, measurable levels of C-peptide ob-
served with glibenclamide, but not gliclazide, is consistent with a greater insulinotropic effect of the former.

Alternatively, it is intriguing to speculate that the drug differences may also reflect the negative consequence of increased skeletal muscle $K_{\text{ATP}}$ activity on whole-body glucose disposal. Increasing evidence implicates a role for the skeletal muscle $K_{\text{ATP}}$ (Kir6.2 and SUR2A) in glucose uptake. An increase in glucose uptake was recently reported in isolated skeletal muscle and adipose tissue from Kir6.2 and SUR2A null mice (31, 39), and inhibitory SUs have previously been shown to directly increase both glucose uptake and peripheral insulin sensitivity (16, 40). These data implicate an antagonistic association between skeletal muscle $K_{\text{ATP}}$ activity and insulin sensitivity. The prediction is that $K_{\text{ATP}}$ overactivity in skeletal muscle, expected in neonatal diabetes mellitus patients with activating Kir6.2 mutations, may actually reduce insulin sensitivity and contribute to the diabetes. The better metabolic control observed with glibenclamide vs. gliclazide in the G53D patient may reflect the specific ability of glibenclamide, but not gliclazide, to inhibit skeletal muscle $K_{\text{ATP}}$ (Fig. 4) and improve insulin sensitivity. Currently it is unknown whether peripheral insulin insensitivity compounds the primary $\beta$-cell defect in carriers of activating Kir6.2 mutations. Interestingly, a recent control-based study demonstrated impaired insulin sensitivity in four, nonobese PNDM patients with the activating R201H mutation (29, 35). If peripheral insulin insensitivity is indeed a common feature of $K_{\text{ATP}}$-induced diabetes, this could have significant clinical implications and alter pharmacological strategies to treat the diabetes both in terms of the type of sulfonylurea used and the dosing.

Correlating Kir6.2 overactivity with disease severity

Previous studies have demonstrated that other mutations of the G53 residue in Kir6.2 (G53S, G53R) decrease ATP sensitivity and underlie TNDM (7). In the current study, we described functional properties of the DEND-causing G53D mutation. ATP sensitivity is decreased approximately 20-fold in G53D homomeric channels, compared with an approximately 5-fold decrease previously reported for both the TNDM-associated G53S and G53R mutations (7). These data are consistent with the premise that the greater the channel overactivity, the greater the suppression of glucose-sensing by the pancreatic $\beta$-cell, and the more severe the diabetes (PNDM/DEND vs. TNDM). Theoretically, all Kir6.2 activating mutations should underlie a diabetic phenotype; in general, however, only the more severe activating mutations are associated with DEND symptoms (although extrapancreatic tissues might respond before the pancreas). This suggests that extrapancreatic tissues (muscle, nerve, and brain) are less sensitive to changes in $K_{\text{ATP}}$ activity than the pancreatic $\beta$-cell and that a threshold of channel overactivity must be reached before neurological features become evident.

Conclusion

The present study highlights the potential added benefit of treating DEND patients with SUs and mechanistically attributes this improved motor function with targeting of the skeletal muscle $K_{\text{ATP}}$. There are a few other reports of improved neurological features in DEND patients with activating Kir6.2 mutations and no report of such improvement in an adult. Future clinical studies are required to evaluate the effectiveness of different sulfonylureas to treat neurological features in both adult and infant populations with DEND syndrome due to Kir6.2 mutations.

Acknowledgments

Address all correspondence and requests for reprints to: Joseph C. Koster, Ph.D., Washington University School of Medicine, Department of Cell Biology and Physiology, Box 8228, St. Louis, MO 63110. E-mail: jkoster@cellbiology.wustl.edu; or Fabrizio Barbetti, M.D., Ph.D., S. Raffaele Scientific Foundation, Room B303, Via di Castelromano, 100, 00128 Rome, Italy. E-mail: fabrizio.barbetti@ssp-r.it.

This work was supported by National Institutes of Health Grant DK069445 (to C.G.N.) and National Institutes of Health Diabetes Research and Training Grant DK-20579. F.B. and F.C. are members of the Early Onset Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetology.

Disclosure Information: All authors have nothing to declare.

References